Log in

Oxford Immunotec Global Stock Forecast, Price & News

+0.29 (+2.03 %)
(As of 12/1/2020 12:00 AM ET)
Today's Range
Now: $14.56
50-Day Range
MA: $12.94
52-Week Range
Now: $14.56
Volume115,987 shs
Average Volume184,024 shs
Market Capitalization$378.01 million
P/E RatioN/A
Dividend YieldN/A
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Oxford Immunotec Global logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.94 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:OXFD



Sales & Book Value

Annual Sales$73.71 million
Cash Flow$0.02 per share
Book Value$8.08 per share


Net Income$-1,810,000.00


Market Cap$378.01 million
Next Earnings Date3/1/2021 (Estimated)
OptionableNot Optionable
+0.29 (+2.03 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

How has Oxford Immunotec Global's stock been impacted by Coronavirus (COVID-19)?

Oxford Immunotec Global's stock was trading at $12.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OXFD stock has increased by 19.4% and is now trading at $14.56.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Oxford Immunotec Global?

Wall Street analysts have given Oxford Immunotec Global a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oxford Immunotec Global wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Oxford Immunotec Global

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) posted its earnings results on Tuesday, November, 3rd. The company reported ($0.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.01). Oxford Immunotec Global had a negative return on equity of 7.52% and a negative net margin of 28.12%.
View Oxford Immunotec Global's earnings history

What guidance has Oxford Immunotec Global issued on next quarter's earnings?

Oxford Immunotec Global updated its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $19-20 million, compared to the consensus revenue estimate of $18.83 million.

Who are some of Oxford Immunotec Global's key competitors?

What other stocks do shareholders of Oxford Immunotec Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Dynavax Technologies (DVAX), AbbVie (ABBV), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Immunomedics (IMMU), Intel (INTC), Iovance Biotherapeutics (IOVA), Gold Resource (GORO), Inovio Pharmaceuticals (INO) and Netflix (NFLX).

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the following people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 46, Pay $1.11M)
  • Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 43, Pay $527.45k)
  • Ms. Janet Louise Kidd, Gen. Counsel & Company Sec. (Age 50)
  • Dr. Peter Edwardson, Sr. VP & Head of Blood Screening (Age 58)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 59)

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

Who are Oxford Immunotec Global's major shareholders?

Oxford Immunotec Global's stock is owned by a variety of retail and institutional investors. Top institutional investors include First Light Asset Management LLC (17.87%), Grandeur Peak Global Advisors LLC (6.68%), Penn Capital Management Co. Inc. (3.54%), New York State Common Retirement Fund (1.47%), WINTON GROUP Ltd (0.57%) and HighMark Wealth Management LLC (0.52%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Patrick J Balthrop, Peter Wrighton-Smith and Richard A Sandberg.
View institutional ownership trends for Oxford Immunotec Global

Which institutional investors are selling Oxford Immunotec Global stock?

OXFD stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Morgan Stanley, JPMorgan Chase & Co., Acadian Asset Management LLC, Trexquant Investment LP, WINTON GROUP Ltd, Connor Clark & Lunn Investment Management Ltd., and Aigen Investment Management LP.
View insider buying and selling activity for Oxford Immunotec Global

Which institutional investors are buying Oxford Immunotec Global stock?

OXFD stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Grandeur Peak Global Advisors LLC, GSA Capital Partners LLP, ExodusPoint Capital Management LP, HighMark Wealth Management LLC, First Light Asset Management LLC, Essex Investment Management Co. LLC, and California Public Employees Retirement System. Company insiders that have bought Oxford Immunotec Global stock in the last two years include Patrick J Balthrop, and Peter Wrighton-Smith.
View insider buying and selling activity for Oxford Immunotec Global

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $14.56.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $378.01 million and generates $73.71 million in revenue each year. The company earns $-1,810,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Oxford Immunotec Global employs 273 workers across the globe.

What is Oxford Immunotec Global's official website?

The official website for Oxford Immunotec Global is www.oxfordimmunotec.com.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.